Digestive diseases and sciences · 2026
Comparative Effectiveness of Biologic Therapies in Chronic Pouchitis and Crohn's-Like Disease of the Pouch: A Bi-center Retrospective Cohort Study.
СтатьяМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uchitel Yoav, Cohen Nathaniel Aviv, Hirsch Ayal, Tulchinsky Hagit, Zemel Meir, Har-Shefi Tzvi, Koslowsky Benjamin, Werner Lael, Maharshak Nitsan
Аннотация
BACKGROUND: Chronic pouchitis and Crohn's-like disease of the pouch are frequent complications following restorative total proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). Biologics are increasingly used in refractory cases, but head-to-head comparative effectiveness data between biologic therapies are limited.
AIMS: We aimed to compare week 52 clinical response and long-term treatment persistence among patients treated with vedolizumab, ustekinumab, or adalimumab.
METHODS: This retrospective bi-center cohort study included adult patients with chronic pouchitis or Crohn's-like disease of the pouch with mPDAI ≥ 5 at biologic initiation. The primary endpoint was week 52 clinical response based on cPDAI, defined as a ≥ 1-point reduction from baseline. Key secondary endpoints were treatment persistence and week 52 mPDAI response (≥ 2-point reduction). Additional secondary endpoints included cPDAI remission, mPDAI remission, ePDAI response and remission, and biochemical outcomes. Between-group comparisons were performed using chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables, with post hoc pairwise comparisons adjusted for multiple testing. Treatment persistence was analyzed using Kaplan-Meier survival curves with log-rank test.
RESULTS: Seventy-seven patients were included (vedolizumab n = 36; ustekinumab n = 22; adalimumab n = 19). Baseline characteristics including distribution of chronic pouchitis and Crohn's-like disease of the pouch were broadly comparable across groups, although ustekinumab was more frequently used as third-line therapy (p = 0.001). At week 52, cPDAI response occurred in 88.9% of patients treated with ustekinumab, 44.8% treated with vedolizumab, and 56.3% treated with adalimumab (p = 0.01). cPDAI remission was achieved in 33.3% of ustekinumab-treated patients, 13.8% of vedolizumab-treated patients, and 6.3% of adalimumab-treated patients (p = 0.09). No statistically significant differences were observed in biochemical remission across groups. Three-year treatment persistence was highest in the ustekinumab group (81.5%) compared with adalimumab (52%) and vedolizumab (35%) (p = 0.01).
CONCLUSIONS: In this real-world cohort, ustekinumab was associated with numerically higher long-term clinical response and treatment persistence compared with vedolizumab or adalimumab. These findings support the need for prospective trials to guide biologic selection in chronic pouchitis and Crohn's-like disease of the pouch.
AIMS: We aimed to compare week 52 clinical response and long-term treatment persistence among patients treated with vedolizumab, ustekinumab, or adalimumab.
METHODS: This retrospective bi-center cohort study included adult patients with chronic pouchitis or Crohn's-like disease of the pouch with mPDAI ≥ 5 at biologic initiation. The primary endpoint was week 52 clinical response based on cPDAI, defined as a ≥ 1-point reduction from baseline. Key secondary endpoints were treatment persistence and week 52 mPDAI response (≥ 2-point reduction). Additional secondary endpoints included cPDAI remission, mPDAI remission, ePDAI response and remission, and biochemical outcomes. Between-group comparisons were performed using chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables, with post hoc pairwise comparisons adjusted for multiple testing. Treatment persistence was analyzed using Kaplan-Meier survival curves with log-rank test.
RESULTS: Seventy-seven patients were included (vedolizumab n = 36; ustekinumab n = 22; adalimumab n = 19). Baseline characteristics including distribution of chronic pouchitis and Crohn's-like disease of the pouch were broadly comparable across groups, although ustekinumab was more frequently used as third-line therapy (p = 0.001). At week 52, cPDAI response occurred in 88.9% of patients treated with ustekinumab, 44.8% treated with vedolizumab, and 56.3% treated with adalimumab (p = 0.01). cPDAI remission was achieved in 33.3% of ustekinumab-treated patients, 13.8% of vedolizumab-treated patients, and 6.3% of adalimumab-treated patients (p = 0.09). No statistically significant differences were observed in biochemical remission across groups. Three-year treatment persistence was highest in the ustekinumab group (81.5%) compared with adalimumab (52%) and vedolizumab (35%) (p = 0.01).
CONCLUSIONS: In this real-world cohort, ustekinumab was associated with numerically higher long-term clinical response and treatment persistence compared with vedolizumab or adalimumab. These findings support the need for prospective trials to guide biologic selection in chronic pouchitis and Crohn's-like disease of the pouch.